Während sich in der Altersgruppe zwischen 55 und 64 Jahren etwa 2–3 Schlaganfälle pro 1 000 Menschen und Jahr ereignen, liegt die Rate bei den über 85–Jährigen 10–fach höher. Kardiovaskuläre Erkrankungen wie arterielle Hypertonie, Hypercholesterinämie und Diabetes mellitus sind mit einem erhöhten Schlaganfallrisiko assoziiert. Sowohl die Anzahl der Erkrankten als auch die der Neuerkrankungen nimmt mit dem Alter zu. Frühzeitige Therapie und fortwährende konsequente Optimierung können Schlaganfällen vorbeugen. Gleichzeitig können durch die Verhinderung zerebraler Durchblutungsstörungen Entstehung und Progression einer vaskulären Demenz verhindert werden. Sie zählt mit der Alzheimer–Erkrankung zu den häufigsten Demenzformen. Nach bereits stattgehabtem Schlaganfall erleidet etwa 1 von 10 Patienten bereits im 1. Jahr ein Rezidiv. Die Sekundärprophylaxe besteht neben der Behandlung der Risikofaktoren vor allem in der Thrombozytenaggregationshemmung bei atherosklerotisch bedingten Ischämien bzw. in der oralen Antikoagulation bei kardioembolischen Infarkten. Die Akuttherapie des Schlaganfalls kann durch das gerinnselauflösende rtPA (recombinant tissue Plasminogen Activator, Actilyse®) erfolgen. Bislang galt ein Alter von > 80 Jahre aufgrund des erhöhten Blutungsrisikos als Kontraindikation. Neueren Untersuchungen zufolge kann der protektive Effekt von rtPA auch bei älteren Patienten deutlich überwiegen. Gleiches gilt für die Sekundärprophylaxe mit oralen Antikoagulanzien. Der seltene hämorrhagische Schlaganfall (d. h. durch eine Blutung) soll im folgenden Übersichtsartikel nicht abgehandelt werden.
While incidence of stroke in patients 55 to 64 years of age is 2–3 per 1 000 people and per year, this rate is 10fold higher in patients 85 years of age or above. Concomitant cardiovascular diseases, e. g. arterial hypertension, diabetes mellitus and hypercholesterinaemia, increase the risk for stroke. Both prevalence and incidence increase with age. Early treatment and continuous optimisation of these risk factors can prevent stroke. Prevention of cerebro–vascular complications reduces the development and progression of vascular dementia. It is one of the most frequent subtypes of dementia along with Alzheimer's disease. After recent stroke, one out of ten patients is likely to suffer from another event within the first year. Besides treatment of risk factors, secondary prevention mainly consists of platelet aggregation inhibitors after atherosclerotic stroke, and oral anticoagulation after cardio–embolic stroke. For acute therapy of stroke the fibrinolytic drug rtPA (Actilyse®) can be applied. Age above 80 years has been an exclusion criterion so far. However, recent investigations clearly indicate that the protective effect of rtPA may outweigh the bleeding risk. The same can be stated for the secondary stroke prevention with oral anticoagulants. Hemorrhagic stroke will not be discussed in this article.
Key words
Stroke - elderly patients - therapy - prevention
Literatur
-
1
Amarenco P. et al. .
Stroke Prevention by Agressive Reduction in Cholesterol Levels (SPARCL) Investigators. High–dose atorvastatin after stroke or transient ischemic attack.
N Engl J Med.
2006;
355
549-559
-
2
Ansell J. et al. .
Managing oral anticoagulant therapy.
Chest.
2001;
119
-
3
Antithrombotic Trialists' Collaboration. .
Collaborative meta–analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients.
Brit Med J.
2002;
524
71-86
-
4
Berge E. et al. .
Low molecular–weight heparin versus aspirin in patients with acute ischaemic stroke and atrial fibrillation: a double–blind randomised study. HAEST Study Group. Heparin in Acute Embolic Stroke Trial.
Lancet.
2000;
355
1205-1210
-
5
Berrouschot J. et al. .
Outcome and severe hemorrhagic complications of intravenous thrombolysis with tissue plasminogen activator in very old (> or = 80 years) stroke patients.
Stroke.
2005;
36
2421-2425
-
6
Bowman TS. et al. .
Blood pressure measures and risk of total, ischemic, and hemorrhagic stroke in men.
Neurology.
2006;
67
820-823
-
7
Cannegieter SC. et al. .
Optimal oral anticoagulant therapy in patients with mechanical heart valves.
N Engl J Med.
1995;
333
11-17
-
8
CAPRIE Steering Committee. .
A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE).
Lancet.
1996;
348
1329-1339
-
9
Colhoun HM. et al. .
Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo–controlled trial.
Lancet.
2004;
364
685-696
-
10
Coutts SB. et al. .
Triaging transient ischemic attack and minor stroke patients using acute magnetic resonance imaging.
Ann Neurol.
2005;
57
848-854
-
11
Dahlof B. et al. .
Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.
Lancet.
2002;
359
995-1003
-
12
Denti L. et al. .
Outcome predictors of rehabilitation for first stroke in the elderly.
Eur J Phys Rehabil Med.
2008;
44
3-11
-
13
Diener HC. et al. .
European Stroke Prevention Study 2: Efficacy and safety data.
J Neurol Sci.
1997;
151
-
14
Diener H. et al. .
Acetylsalicylic acid on a background of clopidogrel in high–risk patients randomised after recent ischaemic stroke or transient ischaemic attack: The MATCH trial results.
Lancet.
2004;
364
331-334
-
15
Diener HC. et al. .
Clopidogrel for secondary prevention of stroke.
Expert Opin Pharmacother.
2005;
6
755-764
-
16
Diener HC. et al. .
Leitlinien der Deutschen Gesellschaft für Neurologie und der Deutschen Schlaganfallgesellschaft zur Primär– und Sekundräprävention des Schlaganfalls: Aktualisierung 2007.
Akt Neurol.
2007;
34
8-12
-
17
Foulkes MA. et al. .
The Stroke Data Bank: design, methods, and baseline characteristics.
Stroke.
1988;
19
547-554
-
18
Franklin SS. et al. .
Predominance of isolated systolic hypertension among middle–aged and elderly US hypertensives: analysis based on National Health and Nutrition Examination Survey (NHANES) III.
Hypertension.
2001;
34
869-874
-
19
Gerstein HC. et al. .
The relationship between dysglycaemia and cardiovascular and renal risk in diabetic and non–diabetic participants in the HOPE study: a prospective epidemiological analysis.
Diabetologia.
2005;
48
1749-1755
-
20
Goldstein LB. et al. .
Primary prevention of ischemic stroke: A statement for healthcare professionals from the Stroke Council of the American Heart Association.
Stroke.
2001;
32
280-299
-
21
Gorter JW..
Major bleeding during anticoagulation after cerebral ischemia: patterns and risk factors. Stroke Prevention in Reversible Ischemia Trial (SPIRIT). European Atrial Fibrillation Trial (EAFT) Study Groups.
Neurology.
1999;
53
1319-1327
-
22
Gueyffler F. et al. .
Antihypertensive drugs in very old people: a subgroup meta–analysis of randomised controlled trials. INDIANA Group.
Lancet.
1999;
353
793-796
-
23
Halliday A. et al. .
Prevention of disabling and fatal strokes by successful carotid endarterectomy in patients without recent neurological symptoms: randomised controlled trial.
Lancet.
2004;
363
1491-1502
-
24
Handke M. et al. .
Patent foramen ovale and cryptogenic stroke in older patients.
N Engl J Med.
2007;
357
2262-2268
-
25
Hart R. et al. .
Antithrombotic therapy to prevent stroke in patients with atrial fibrillation: a meta–analysis.
Ann Intern Med.
1999;
131
492-501
-
26
Hart RG. et al. .
Aspirin for the primary prevention of stroke and other major vascular events. Meta–analysis and hypotheses.
Arch Neurol.
2000;
57
326-332
-
27
Hart RG. et al. .
Atrial fibrillation, stroke, and acute antithrombotic therapy: analysis of randomized clinical trials.
Stroke.
2002;
33
2722-2727
-
28
International Stroke Trial (IST) Collaborative Group. .
The International Stroke Trial (IST): a randomised trial of aspirin, subcutaneous heparin, both or neither among 19435 patients with acute ischaemic stroke.
Lancet.
1997;
349
1569-1581
-
29
Kagiyama S. et al. .
Association between blood pressure and mortality in 80–year–old subjects from a population–based prospective study in Japan.
Hypertens Res.
2008;
31
265-270
-
30
Kawachi I. et al. .
Smoking cessation and decreased risk of stroke in women.
JAMA.
1993;
269
232-236
-
31
Kolominsky–Rabas PL. et al. .
A prospective community–based study of stroke in Germany – the Erlangen Stroke Project (ESPro): incidence and case fatality at 1, 3, and 12 months.
Stroke.
1998;
29
2501-2506
-
32
Lee IM. et al. .
Exercise and risk of stroke in male physicians.
Stroke.
1999;
30
1-6
-
33
Lovett JK. et al. .
Early risk of recurrence by subtype of ischemic stroke in population–based incidence studies.
Neurology.
2004;
62
569-573
-
34
Markus HS. et al. .
Dual antiplatelet therapy with clopidogrel and aspirin in symptomatic carotid stenosis evaluated using doppler embolic signal detection: the Clopidogrel and Aspirin for Reduction of Emboli in Symptomatic Carotid Stenosis (CARESS) trial.
Circulation.
2005;
111
2233-2040
-
35
Mas al JL et. Patent Foramen Ovale and Atrial Septal Aneurysm Study Group. .
Recurrent cerebrovascular events associated with patent foramen ovale, atrial septal aneurysm, or both.
N Engl J Med.
2001;
345
1740-1746
-
36
Messé SR. et al. .
Practice parameter: recurrent stroke with patent foramen ovale and atrial septal aneurysm: report of the Quality Standards Subcommittee of the American Academy of Neurology.
Neurology.
2004;
62
1042-1050
-
37
Poli D. et al. .
Risk of bleeding in very old atrial fibrillation patients on warfarin: Relationship with ageing and CHADS2 score.
Thromb Res.
2007;
121
347-352
-
38
PRoFESS trial working group (2008). .
Secondary stroke prevention set to benefit from PRoFESS trial: extended–release dipyridamole plus aspirin (Asasantin Retard) and clopidogrel share very similar benefit–risk ratio in vascular prevention.
Cardiovasc J Afr.
2008;
19
165
-
39
Progress Collaborative Group (2001). .
Randomised trial of a perindopril–based blood–pressure lowering regimen among 6105 individuals with previous stroke or transient ischaemic attack.
Lancet.
2001;
358
1033-1041
-
40
Reboldi G. et al. .
Comparison between angiotensin–converting enzyme inhibitors and angiotensin receptor blockers on the risk of myocardial infarction, stroke and death: a meta–analysis.
J Hypertens.
2008;
26
1282-1289
-
41
Ridker PM. et al. .
A randomized trial of low–dose aspirin in the primary prevention of cardiovascular disease in women.
N Engl J Med.
2005;
352
1293-1304
-
42
Ringleb PA. et al. .
Benefit of clopidogrel over aspirin is amplified in patients with a history of ischemic events.
Stroke.
2004;
35
528-532
-
43
Ringleb PA. et al. .
Safety of endovascular treatment of carotid artery stenosis compared with surgical treatment: a meta–analysis.
J Vasc Surg.
2008;
47
350-355
-
44
Rothwell PM, Warlow CP..
Prediction of benefit from carotid endarterectomy in individual patients: a risk–modelling study. European Carotid Surgery Trialists' Collaborative Group.
Lancet.
1999;
353
2105-2110
-
45
Stein PD. et al. .
Antithrombotic therapy in patients with mechanical and biological prosthetic heart valves.
Chest.
2001;
119
-
46
Stella F. et al. .
Risk factors for vascular dementia in elderly psychiatric outpatients with preserved cognitive functions.
J Neurol Sci.
2007;
257
247-249
-
47
Wang JG. et al. .
Prevention of stroke and myocardial infarction by amlodipine and Angiotensin receptor blockers: a quantitative overview.
Hypertension.
2007;
50
181-188
-
48
Wang JG. et al. .
Carotid intima–media thickness and antihypertensive treatment: a meta–analysis of randomized controlled trials.
Stroke.
2006;
34
1933-1940
-
49
Wardlaw JM. et al. .
Non–invasive imaging compared with intra–arterial angiography in the diagnosis of symptomatic carotid stenosis: a meta–analysis.
Lancet.
2006;
367
1503-1512
-
50
Wiesmann M. et al. .
Stent–protected angioplasty versus carotid endarterectomy in patients with carotid artery stenosis: meta–analysis of randomized trial data.
Eur Radiol.
2008;
18
2956-2966
-
51 Wolf PA. et al. .Epidemiology of stroke. In: Barnett HJM, Mohr JP, Stein BM, Yatsu FM, Editors: Stroke: Pathophysiology, Diagnosis and Management. 3rd ed. New York: Churchill Livingston 3-27
-
52
Yadav JS. et al. .
Protected carotid–artery stenting versus endarterectomy in high–risk patients.
N Engl J Med.
2004;
351
1493-1501
1 National Institute of Health Stroke Scale
Korrespondenz
Dr. med. Hjoerdis Hentschel
Klinik und Poliklinik für Neurologie Universitätsklinikum Carl Gustav Carus
Fetscherstr. 74
01307 Dresden
eMail: Hjoerdis.Hentschel@neuro.med.tu-dresden.de
